Navigation Links
Velico Medical Announces a Further $18.9m BARDA Funding for Spray Dried Alternative to Frozen Plasma

Velico Medical, today announced a further $18.9m of funding from the Biomedical Advanced Research and Development Authority (BARDA, US Department of Health and Human Services) for their patented, dried plasma technology. BARDA has exercised its third option under a contract with Velico which extends through November 2019 and provides for up to approximately $18.9 million of additional funding raising the total value of its commitment to Velico to $46.5 million. This phase of the contract supports commercial development of a system, targeted for deployment in blood collection and processing centers in the United States and around the world, which enables spray drying of human plasma for transfusion. Currently the industry norm is to freeze plasma which can take up to 40 minutes or more to defrost and deliver. Spray dried plasma is expected to be an easy to prepare, easy to use alternative to frozen plasma for all civilian (OR, ER, ICU) and military applications. This includes extending availability outside of the hospital to emergency first responders and for use in mass casualty events

“Despite advances in transfusion medicine and trauma resuscitation, massive blood loss remains a major cause of mortality, both in developed and developing countries. Velico’s breakthrough technology is poised to improve the survival rate of patients suffering from blood loss, extending the ‘golden hour’ of successful intervention to the pre-hospital setting” says Dr. Mark Popovsky, Velico’s Chief Medical Officer.

“A dry plasma product is our greatest need right now, from field military operations to supporting emergency care in rural America to advancing the life-saving tool kit of Level I trauma centers. Plasma has been shown to have numerous beneficial effects in bleeding patients including stopping bleeding and supporting organ function but it is not currently widely available in the amounts that are needed and this problem is magnified in disaster situations.

Plasma delivered early to a patient makes all the difference. Most hospitals only have three to six units of thawed plasma available. If more is required, then it takes a further 30 minutes or more to thaw – keeping surgeons waiting and putting lives at risk. Velico’s technology enables plasma on-demand, anywhere. Between 5% and 10% more lives could be saved through early introduction of plasma. Dried plasma has the potential to revolutionize transfusion therapy” said Martin A. Schreiber, M.D., Chief of Trauma, Critical Care and Acute Care Surgery at Oregon Health & Science University.

“We believe that BARDA’s approval of the next phase of the contract reflects recognition of Velico’s progress and the life-saving potential of this important technology. Our partnership with BARDA has been collaborative, constructive and has resulted in jointly developed solutions to a number of development challenges. We believe this collaboration has and will continue to deliver significant value for both parties as we finalize development and advance toward clinical trials,” stated Bill Skillman, Velico CEO.

Once commercialized, FrontlineODP™(On Demand Plasma) will be produced by regional blood centers using Velico’s spray drying system. Blood centers have been producing blood products for decades and will play an integral role in meeting the need for a frozen plasma alternative. Blood centers have the infrastructure, experience, and expertise to provide a sustainable source of dried plasma for local use and for linking to national disaster management channels to support disaster recovery in mass casualty events.

BARDA funding of SpDP is non-dilutive to Velico Medical shareholders. This work is being performed under contract HHS0100201200005C funded by the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

About Velico Medical
Velico Medical, Inc. is a private, pre-clinical medical technology company focused on applying proprietary technologies to improving the quality, availability and economics of plasma and platelet transfusions. We are developing two separate product candidates that, if approved, are expected to improve patient outcomes and safety and result in a more effective blood delivery system. Our technologies are expected to solve critical unmet needs in transfusing these life-saving blood products and represent opportunities for significant savings for the healthcare delivery system. The technologies underlying our product candidates are the subject of issued and pending patent applications in countries of commercial consequence to us. Our strategy is to develop, commercialize and market single-use disposables for use in processing and storing plasma and platelets, as well as a companion instrument for spray drying plasma.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Velico Medical Announces BARDA Exercise of $15.5 Million Contract Option
2. Velico Medical Hires Internationally Recognized Transfusion Medicine Expert Mark Popovsky, M.D.
3. Velico Medical Voted “Best in Show” at the 22nd Annual Medtech Investing – Europe Conference
4. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
5. Astute Medical, Inc. ospiterà il simposio sullinsufficienza renale al 33o incontro annuale ISICEM
6. Astute Medical, Inc. organizará el 33. simposio anual en el congreso ISICEM sobre daño renal
7. Astute Medical, INC. ist Veranstalter eines SYMPOSIUMS zu Nierenerkrankungen beim 33. jährlichen ISICEM
8. Astute Medical, Inc. va Accueillir le Symposium portant sur linsuffisance rénale du 33e ISICEM annuel
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Medical Gases and Equipment Market is Expected to Reach USD 9 Billion Globally in 2018: Transparency Market Research
11. Clinical Trials and Medical Research in Texas Create Jobs and Save Lives
Post Your Comments:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
Breaking Biology News(10 mins):